Cellectis S.A. (CLLS) has released an update.
Cellectis S.A., a biotech company specializing in gene therapies, has published groundbreaking research on using gene-edited hematopoietic stem and progenitor cells (HSPCs) to treat metabolic and neurological disorders. Their novel approach, which involves TALEN-mediated intron editing, enables targeted delivery of therapeutic proteins to the brain by exploiting the natural migration of myeloid cells. This technique promises minimal genomic impact and the potential to treat a range of diseases without disrupting normal gene function.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
